We've found
					19,218 Lung Cancer				
					clinical trials				
				
			
		
							
  	
	Oncology Clinical Trial
	Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology, Reproductive Clinical Trial
	QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology, Reproductive Clinical Trial
	QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	NSCLC Clinical Trial
	Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	NSCLC Clinical Trial
	Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	NSCLC Clinical Trial
	Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	NSCLC Clinical Trial
	Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Small Cell Lung Carcinoma Clinical Trial
	Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Lung Cancer Clinical Trial
	Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Mesothelioma Clinical Trial
	Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 10/25/2017	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Advanced Non Small Cell Lung Cancer Clinical Trial
	Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Lung Cancer Screening Clinical Trial
	Lung Cancer Screening Decisions
		Status: Enrolling	
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Lung Cancer Clinical Trial
	Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II
		Status: Enrolling	
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Lung Cancer Clinical Trial
	Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II
		Status: Enrolling	
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Lung Cancer Clinical Trial
	All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules
		Status: Enrolling	
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Lung Cancer Clinical Trial
	All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules
		Status: Enrolling	
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
						
				
			
We've found
					19,218 Lung Cancer
				
					clinical trials
				
				
				
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology, Reproductive Clinical Trial
	
Updated: 12/31/1969
  
  
  QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology, Reproductive Clinical Trial
	
Updated: 12/31/1969
  
  
  QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	NSCLC Clinical Trial
	
Updated: 12/31/1969
  
  
  Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	NSCLC Clinical Trial
	
Updated: 12/31/1969
  
  
  Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	NSCLC Clinical Trial
	
Updated: 12/31/1969
  
  
  Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	NSCLC Clinical Trial
	
Updated: 12/31/1969
  
  
  Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Small Cell Lung Carcinoma Clinical Trial
	
Updated: 12/31/1969
  
  
  Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Lung Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Mesothelioma Clinical Trial
	
Updated: 10/25/2017
  
  
  Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 10/25/2017
Click here to add this to my saved trials
	    
		
	Advanced Non Small Cell Lung Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Lung Cancer Screening Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung Cancer Screening Decisions
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Lung Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Lung Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Lung Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Lung Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials